Oslo, Norway, 4 December 2019 Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical studies investigating the effect of Betalutin® (177Lu-lilotomab satetraxetan) on non-Hodgkin's lymphoma (NHL) cell lines will be presented in a poster at the 61st American Society of H... read more

Stockholm – December 2, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Joseph Horvat has been appointed as President North America and CEO of Oncopetides Inc. Joseph will serve on the Management Team of Oncopeptides and will start today. The appointment of Joseph H... read more

Appointment strengthens Orexo’s competencies and resources within digital health Orexo committed to finding innovative solutions to improve treatment of addiction Uppsala, Sweden – December 2, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim... read more

-Deal further strengthens Orexo’s partnership with GAIA -Orexo committed to digital health to address addiction Uppsala, Sweden – November 27, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addictio... read more

November 19, 2019 - Regulatory press release Press releases Summary Financial overview July 1 – September 30, 2019 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 189.8 M (loss: 94.0) Loss per share, before and after dilution, was SEK 3.53 (loss: 2.14) ... read more